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The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated disease (COVID-19)
outbreak seriously challenges globally all health care systems and professionals. Expert projections es-
timate that despite social distancing and lockdown being practiced, we have yet to feel the full impact of
COVID-19. In this manuscript we provide guidance to prepare for the impact of COVID-19 pandemic on
breast cancer patients and advise on how to triage, prioritize and organize diagnostic procedures, sur-
gical, radiation and medical treatments.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The outbreak of the severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) associated disease (COVID-19) has rapidly
escalated to pandemic proportions. By the beginning of April 2020,
over 1,000,000 cases of confirmed infections and over 66,000
deaths from COVID-19 were reported worldwide [www.
worldometers.info/coronavirus]. The most common symptoms of
COVID-19 are new onset of a continuous cough and/or temperature
37.8 C [1]. Ageusia and anosmia are also frequent symptoms at
the early phase of diagnosis [1]. While most patients have no orDevelopment for Innovative
versity of Milan, Department
amonti n. 435, 20141, Milan,
igliano).
nuscript writing, editing and
r Ltd. This is an open access articlemild symptoms, about a quarter of patients develop severe symp-
toms and 5% will have critical symptoms. The clinical manifesta-
tions, as well as case fatality rates have been higher in the elderly,
those with comorbidities such as respiratory and cardiovascular
disease, males and smokers [2]. There is currently no approved nor
proven effective treatment or vaccine available for COVID-19, but
there are several ongoing trials of potential therapies.
COVID-19 has led to a severe overloading of hospital systems in
most affected regions and countries [3]. Healthcare resources
(human as well as material) have been rearranged to manage the
influx of a large number of patients requiring intensive monitoring,
artificial ventilation, and in selected cases extracorporeal mem-
brane oxygenation [4]. Even in countries where COVID19 has not
attained very high incidence rates, containment measures are
recommended and are being implemented, to prevent infections
both of patients and healthcare professionals. The response to this
pandemic has led to a sudden disruption of routine medical care,
including the treatment of cancer patients, an especially vulnerable
population, whose outcomes are dependent on timely and high-under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Fig. 1. PDCA is an iterative four-step management method aimed at continuous
improvement of processes [7].
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made it difficult for some cancer patients to reach the hospital and
the fear of infection while visiting the hospital has caused many
others to cancel their appointments. Staffing gaps within the
oncology departments have arisen as a result of redeployment and
sequestering of medical and supporting staff to other areas of
critical need e such as respiratory units, emergency departments,
and intensive care units (ICUs), as well as self-isolation or quaran-
tine of staff members with suspicious symptoms and/or positive
SARS-CoV-2 test [6]. Consequently, many routine visits to the
outpatient clinics have been either replaced by telephone/video
consultation or deferred.
Independently of whether in a general hospital or in an
oncology facility, measures need to be put in place to protect pa-
tients and health professionals, and to create a safe circuit to treat
or transfer (according to country/regional directives) SARS-CoV-2
infected patients with cancer. These actions have also a strong
impact on available resources and routine processes that need to be
considered to avoid system disruption.
As breast cancer specialists, our main goal is to take care of
breast cancer patients within a multidisciplinary environment, able
to provide high level treatment within the shortest period of time
and according to established quality indicators. However, the cur-
rent extraordinary worldwide situation requires an urgent re-
organization and adapted allocation of healthcare resources, staff
as well as infrastructures without compromising patients’
outcomes.
The aim of the present recommendations is to provide guide-
lines, including selection criteria to service provision and prioriti-
zation of treatments, according to the pandemic scenario in each
country/region (Table 1), for breast cancer patients care during this
critical moment when benefits and risks are influenced by a serious
external health threat. This necessitates that all current medical
decisions must be carefully weighed taking into account unusualTable 1
Scenarios to describe progression of COVID-19 outbreaks - according to ECDC.parameters and be balanced not only for the safety of individual
patients but also for the community. The PDCA
(planedoecheckeact or planedoecheckeadjust) approach is
aimed at continuously following, monitoring and improving the
organization based on the obtained results in every single hospital
and/or department (Fig. 1).
Therefore, the following proposals must be interpreted as
extraordinary, limited to the duration of the contingent pandemic
situation, and should be adapted to national/regional circum-
stances taking into account existing public health regulations. We
G. Curigliano et al. / The Breast 52 (2020) 8e1610highlight that these considerations do not overcome the individual
physician judgment or available treatment guidelines but represent
an expert-opinion-based guidance for optimal allocation of re-
sources during an unprecedented critical period, drawing on cur-
rent knowledge in a rapidly emerging and evolving situation.1.1. Proposed risk stratifications [8,9]
I) Breast cancer patients recently suspected or recently
diagnosed
II) Breast cancer patients on active treatment (i.e. chemo-
therapy, immunotherapy, anti-HER2 therapy, endocrine
therapy with or without targeted therapies)
III) Breast cancer patients in follow-up (non-active treatment) or
on adjuvant endocrine therapy alone
Supplementary risk factors: age over 60/pre-existing cardio-
vascular disease/pre-existing respiratory disease/smokers/males.1.2. General recommendations (Table 2)
1. Patients should be informed and guided to follow all measures
of social distancing and wearing personal protective equipment
(i.e. mask) when travelling to the hospital, always in compliance
with each country public health regulations.
2. Early identification of symptoms suspicious of SARS-CoV-2
infection is crucial, as well as of symptoms or adverse events
caused by the malignancy or antitumor treatments. This pre-
screening can be done by phone before each appointment at
the hospital and/or at the entry of the hospital. Body tempera-
ture should be measured at the entry of the hospital. Patients
with symptoms suspicious of SARS-CoV-2 infection, should be
tested and managed in a COVID-19 hospital or in the COVID-19-
dedicated departments/areas of the cancer center.
3. Patients who need to be hospitalized for cancer treatment
should be treated in COVID-19-free hospitals or COVID-19-free
departments/areas of the hospital and be, as much as possible,
shielded from potential SARS-CoV-2 infection, with a dedicated
diagnostic and therapeutic internal pathway.
4. No visits should be allowed in the inpatient facilities and no
accompanying care giver should enter the hospital with the
patient for appointments or treatments.
5. Staff should be organized by shifts, limiting the number of
people working simultaneously to the minimum required.
6. The multidisciplinary tumour boards (MDM) should be
continued but performed via web meetings or restricted to one
element of each discipline of the core team [10]. All decisions of
the MDM should continue to be discussed with the patient and
the final decision must account for the patients’ preferences.
7. Due to different availability of tests and different public health
measures taken in each country, we recommend that testing
guidelines of the national health authorities are followed. If tests
are available, patients should be tested for SARS-CoV-2 before
surgery or any invasive procedure and before initiating immu-
nosuppressive therapies, independently of symptoms. If posi-
tive, the procedure and/or treatment should be postponed and
resumed only after the patient is considered recovered. How-
ever, it is important to realize that even with this approach,
some cases will be missed in view of the false negative rate of
the PCR test on pharyngeal swabs.1.3. Screening and diagnosis (Table 2)
1. Due to the foreseeable reduction of resources and to ensure the
safety of patients and staff, population mammographic
screening should be suspended until the pandemic has subsided
[4,5,11,12].
2. Diagnostic procedures in symptomatic patients should be
scheduled according to local availability and resources. How-
ever, all efforts should be made to avoid delayed diagnosis in
those with suspicious symptoms or clinical or imaging findings
[BIRADS 5 (high priority) or BIRADS 4 (medium priority)] and its
potential impact on cancer outcomes [4,5,11,12].1.4. Locoregional treatment in early breast cancer (EBC)
1.4.1. Surgery versus primary systemic treatment (Table 3)
Under normal circumstances, primary systemic therapy (PST) is
increasingly used and preferred over upfront surgery, not only for
locally advanced disease but also in the EBC setting, both within
and outside clinical trials. This is due to the established benefits of
this approach in terms of surgical de-escalation and more recently
to optimize further adjuvant treatments. PST includes both neo-
adjuvant/primary chemotherapy ± anti-HER2 therapy (NAC) and
neo-adjuvant/primary endocrine therapy (PET).
During the COVID-19 pandemic, PST indications in EBC patients
may be temporarily reconsidered taking into account the avail-
ability of facilities and healthcare resources, the number of required
hospital visits and the risks of compromising the immune system
associated with different type of treatments [9,12e14]. The situa-
tion might widely vary according to different countries but also in
different cities and different hospitals. Therefore, it is even more
critical that indications for treatment are taken in a multidisci-
plinary setting, in light of what is deemed to be the best option for
each patient in that specific time and place. A crucial balance is
needed between maintaining a high quality of breast cancer care,
not jeopardizing cancer outcomes, andminimising both the risks of
infection by SARS-CoV-2 and the risks of complications of anti-
cancer treatments. The decision between primary surgery or PST
should also take into account the pandemic scenario (Table 1) in
each center (i.e. early stages vs mitigation phase vs recovery phase).
For instance, some patients with EBC who under normal circum-
stances would receive PST might be treated with primary surgery
especially when a limited procedure is feasible in an outpatient
setting. In contrast, some patients who, under normal circum-
stances, could be treated with primary surgery, such as post-
menopausal women with limited luminal A/B disease, might be
treated with primary endocrine therapy in order to delay invasive
procedures and hospitalization.1.5. Surgery (Table 3)
At this point in time, when surgery is indicated, preference
should be given to the most effective minimal surgical procedure
with the fastest recovery time, that lower risks for the individual
patient and reduce the need of healthcare resources. These general
recommendations should be applied even in countries where the
outbreak has not yet dramatically affected the health system and
the surgical activity is still maintained with a reduction that is less
than half the usual production [13,15e17].
1. Defer all benign, cosmetic, and risk-reducing procedures.
2. Offer outpatient surgery whenever possible.
3. Postpone all delayed breast reconstructions.
Table 2
Prioritization of outpatient, screening and diagnostic visits for patients with breast cancer.
Table 3
Prioritization of surgery in patients with breast cancer.
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prolonged hospitalization and/or have a high risk for
complications.
5. In case immediate breast reconstruction is considered, recom-
mend simpler (less intensive) procedures with fast recovery
(microsurgery should not be undertaken e high resources
needed).
The following is meant to be a grid of priority in order to
minimize the possible detrimental effect of treatment delay in a
worst-case scenario when the availability of surgical slots is highly
reduced (e.g. 10e20% of the usual activity). We propose to prioritize
patients with diagnosed malignancy into 4 categories. 1) Urgent:
surgery within 2 weeks; 2) High priority: surgery within 4 weeks;
3) Medium priority: surgery within 8 weeks; 4) Low priority:surgery after 8 weeks allowed.
1. Urgent:
a. Patients with significant tumour burden, not responding or
progressing under PST.
b. Pregnant patients, if surgery upfront was decided by the
multidisciplinary tumour board.
c. Patients with complicated locally advanced tumours not
otherwise manageable.
2. High Priority
a. Patients with early isolated loco-regional recurrence (within
48 months from primary treatment).
b. High-risk patients with contraindications to PST, or node
positive, or with disease showing biological features of
aggressiveness.
G. Curigliano et al. / The Breast 52 (2020) 8e16123. Intermediate Priority
a. Patients treated with PST (ideally at a maximum of 4e6
weeks after treatment completion).
b. Pre-menopausal patients with ER þ tumours and without
indication for preoperative chemotherapy (since neoadjuvant
endocrine therapy is not recommended for these patients
outside of clinical trials).
4. Low Priority
a. Ductal carcinoma in situ (however, high grade ER negative or
very extensive DCIS and/or with palpable lump or extensive
microcalcifications might fall into the intermediate priority
category based on case by case considerations).
b. Post-menopausal patients with Luminal A-like cancer. In
these women primary endocrine therapy could be initiated,
and surgery could be postponed.1.6. Radiation therapy (Table 4)
1.6.1. Early breast cancer (EBC)
Radiation therapy (RT) for breast cancer is most often delivered
after completion of other treatments, including surgery and
chemotherapy. Conventional treatment duration is between 3 and
7 weeks. During the COVID-19 pandemic, we need to contribute to
the statement of the World Health Organization (WHO) “to stop,
contain, control, delay and reduce the impact of this virus at every
opportunity”. This translates into minimising exposure and burden
to both patients and healthcare personnel without compromising
oncological outcome, by minimising the number of hospital visits
and limiting the complexity of RT planning/treatment [18]. A useful
approach during the pandemic is to give preference, to the least
resource-intensive treatment regimen, provided that there are data
supporting the use of this type of regimen.
The following recommendations can be considered and dis-
cussed with the patients, based on the particular circumstances
that may be influenced by social restrictions to contain viral spread,
the proportion of the population that is affected, the percentage ofTable 4
Prioritization of radiotherapy in patients with breast cancer.the personnel that is present and the pre-existing treatment
capacity:
1. Postpone RT up to 3months for high-risk and up to 6months for
low-risk patients [19].
In the past, protocols were based on the common position that
RT should start as soon as possible following surgery in order to
increase treatment efficacy. Following population-based data from
a more recent cohort of breast cancer patients, starting RT shortly
after surgery does not seem to be associated with a better long-
term outcome [19].
2. Moderate hypofractionation should be used for all breast/chest
wall and nodal RT, e.g. 40Gy in 15 fractions over 3 weeks
[19e21].
The use of moderate hypofractionation is already the standard
of care in many countries and in the altered risk-benefit context of a
pandemic should be strongly considered for all patients, including
those after breast reconstruction.
3. Deliver RT in 5 fractions for all patients requiring RT with node
negative tumours that do not require a boost. Options include
28e30Gy in one weekly fraction over 5 weeks or 26Gy in 5 daily
fractions over 1 week as per the FAST and FAST Forward trials,
respectively [22e24].
Five-year local relapse data for FAST Forward will be published
soon but data on 3-year normal tissue toxicity has already been
demonstrated to be equivalent with 40Gy in 15 fractions.
4. Boost RT should be omitted to reduce fractions and/or
complexity in the vast majority of patients unless those 40 years
old and under, or over 40 years with significant risk factors for
local relapse [25].
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survival. An example of a significant risk factor is the presence of
involved resection margins where further surgery is not possible.
Any boost should be with a minimum supplementary number of
fractions or given concurrently with the treatment fractions.
5. Accelerated partial breast RT can also be considered for selected
low-risk patients [26e29].
Accumulating data support the use of partial breast irradiation.
An accelerated schedule like in the Florence trial, using 30Gy in 5
fractions over 2 weeks, suits very well. The duration could be
further reduced by condensing the schedule into a 1-week frac-
tionation schedule (reducing the total dose) or delivery of intra-
operative electron-based RT that is delivered as a one-step
procedure together with the lumpectomy.
6. Omission of RT might be considered in elderly patients at low
risk of recurrence [30].
The elderly constitutes the population at higher risk to develop
severe consequences from COVID-19 and at the same time the
population of patients who derive the less benefits, in absolute
terms, from postoperative RT. This indication, however, should be
evaluated in the light of the local situation and reconsidered for the
individual patient every 4 weeks.
Trials investigating safe omission of RT can be considered if they
do not impact on patient visits and resources are available. Centres
may also consider omitting RT for low-risk ductal carcinoma in-situ
(DCIS) depending on individual risk and benefit.
1.7. Advanced breast cancer (ABC)
For ABC, radiation therapy is urgent for the following situations:
1. Treatment of spinal cord compression.
2. Treatment of brain and leptomeningeal metastases.
3. Palliative treatments (e.g. of bonemetastases) not responding to
pharmaceutical interventions1.8. Systemic therapy (Table 5)
1.8.1. Early breast cancer (EBC)
Early breast cancer can be a fatal disease if left untreated -
adequate surgery combined with appropriate perioperative thera-
pies are essential to increase the probability of cure. For this reason,
treatment of EBC patients should, as much as possible, follow high
quality international clinical guidelines [31]. However, some of the
adjuvant systemic therapies have a significant risk of immuno-
suppression that can have detrimental effects during the COVID-19
pandemic. Some measures can be taken to decrease this potential
detrimental effect:
 When utilizing chemotherapy regimens with intermediate/high
risk of immunosuppression, such as anthracyclines, 3-weekly
docetaxel or 3 weekly platinum, hematopoietic growth factors
can be used to decrease the risk of neutropenia and febrile
neutropenia.
 Steroids use should be limited to the indispensable, to avoid
increasing the risk of immunosuppression.
 To decrease the number of visits to the hospital, 2-weekly (dose-
dense) or 3-weekly regimens should be preferred. However, in
patients above the age of 65 years, the number of visits should
be balanced with the substantially better tolerability of weeklypaclitaxel when compared to 3-weekly docetaxel. Dose-dense
regimens allow for the shortest duration of treatment.
 For triple negative EBC, when deciding on the addition of plat-
inum to anthracyclines and taxanes, the higher haematological
toxicity and consequent risk of immunosuppression of these
agents must be taken into account during this pandemic, in
particular, considering that the potential additional benefit of
these agents is still controversial.
 For HER2þ EBC, the use of anti-HER2 agents is highly recom-
mended, as per guidelines, in view of the substantial survival
benefit and the absence of data suggesting any detrimental ef-
fect of their use during this pandemic. In lower risk patients
shortening trastuzumab administration to half year may be
considered [32], except for those treated with the APT (weekly
paclitaxel and trastuzumab) regimen. Trastuzumab subcutane-
ous formulation is preferred and, when resources allow it, home
administration can be used.
 For ERþ/HER2 negative EBC, the most difficult decision is
related to the use of adjuvant chemotherapy. In cases where the
benefit of this treatment is uncertain, the risk/benefit balance,
during this pandemic, might more often be in favour of not
administering chemotherapy. As for all decision-making process
in oncology, the ultimate decision must be taken by the patient,
after adequate information, since the attitude towards risks and
benefits is highly variable according to individuals’ values and
preferences and may be different in the current pandemic sit-
uation. Genomic tests may be used to help treatment decision-
making in doubtful cases.
 Adjuvant endocrine therapy, including the use of ovarian func-
tion suppression in pre-menopausal women, should follow the
usual international guidelines, since no additional risk is fore-
seen from these agents. In selected cases, 3-monthly adminis-
tration of LHRH agonist can be used, provided that confirmation
of ovarian suppression is done; however, in very young women
and/or women taking an aromatase inhibitor, the risk of inad-
equate ovarian suppression with the 3-monthly administration
is higher. In addition, the administration of an LHRH agonist can
be performed at home, if resources allow it.
 For adjuvant bisphosphonates, oral formulations can be
preferred during this pandemic. Possible delay of administration
or moving the administration earlier, when resources are still
available may also be considered, in particular considering that
the interval of administration of i.v. formulations is every 6
months.1.9. Advanced breast cancer (ABC)
Advanced/metastatic breast cancer is an incurable disease, with
a median survival of about 3 years, varying according to the breast
cancer subtype. In addition, metastatic disease carries in itself some
level of immunosuppression. It is therefore essential that all ABC
patients remain under adequate treatment, according to high
quality international guidelines [33], and close surveillance during
the COVID-19 pandemic. Notwithstanding these facts, some mea-
sures may be taken to decrease the risk of complications and allow
for adequate treatment of these patients.
 Even under normal (non-pandemic) circumstances, the balance
between quantity and quality of life is crucial in the manage-
ment of ABC. This holds equally in the COVID-19 pandemic and
more so where treatment options are being cautiously consid-
ered, underscoring the need for shared decisions with patients.
Dose reductions and dose interruptions should be considered,
whenever the side effects are important. In some cases of
Table 5
Prioritization of systemic treatment in patients with early and metastatic breast.
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may be considered but require active and tight surveillance.
 For ERþ/HER2 negative ABC, endocrine-based therapy is the
preferred choice for the vast majority of patients and should
follow the usual international guidelines, including the
mandatory use of ovarian function suppression in pre-
menopausal women.
 One of the most difficult decisions during the COVID-19
pandemic relates to the addition of CDK 4/6 inhibitors, in view
of their immunosuppressive effect. These agents are now
considered the standard of care for this subtype of breast cancer
but can be used in either 1st or 2nd line. During this pandemic,
the decision to add a CDK 4/6 inhibitor to endocrine therapy
should take into account the burden of metastatic disease, the
pace of disease progression and the possibility of using these
agents later in the course of the disease (situation variable in
different countries).
 The addition of an mTOR inhibitor or a Pi3KCA inhibitor to
endocrine therapy must also take into account their immuno-
suppressive effect and the risk of pneumonitis/interstitial lung
disease and other serious side effects, as well as the lack of
survival benefit seen so far from the use of these agents. Deci-
sion should be made on a case-by-case basis, considering the
burden of metastatic disease, the pace of disease progression,
the possibility of using these agents later in the course of the
disease, and the availability of other therapeutic options.
 When utilizing chemotherapy, preference should be given to
oral agents and agents with lower risk of immunosuppression,
such as capecitabine, including for triple negative or HER2þ
ABC. Vinorelbine can be used in its oral formulation and a dose
reduction can be considered to avoid haematological toxicity.
 In cases where the use of i.v. agents and/or agents with higher
risk of immunosuppression is needed, preference should be
given to liposomal formulations of anthracyclines and 3-weekly
regimens of taxanes or platinum compounds. Once again, the
number of visits should be balanced with the substantially
better tolerability of weekly paclitaxel when compared to 3-
weekly docetaxel, in particular for older and/or less fit pa-
tients. Use of prophylactic hematopoietic growth factors should
also be considered.
 For HER2þ ABC, the use of anti-HER2 agents is highly recom-
mended, as per guidelines, in view of the substantial survival
benefit and the absence of data suggesting any detrimental ef-
fect of their use during this pandemic.
 The use of bone modulating agents should be discussed on a
case-by-cases basis, depending on the burden of bone disease
and the presence/absence of symptoms. In many circumstances,
it is possible to increase the interval of administration of i.v.
bisphosphonates, limiting the number of visits to the hospital
while maintaining a good control of bone metastases. Further-
more, the administration of s.c. denosumab can be performed at
home, if resources allow it.1.10. Psychological Management of Cancer Patients during the
COVID-19 outbreak
The rapid spread of SARS-CoV-2 epidemics and the increased
risk of clinical severe events in cancer patients occur alongside
psychological side effects that worsen patients’ situation. The sig-
nificant psychological impact on oncological patients is com-
pounded by multiple factors during the pandemic e knowledge
that the individual is at higher risk of serious complication if
infected by Covid-19, loneliness and isolation as a result of social
distancing, and the underlying constant fear of the cancer.Loneliness is associated with higher risk of mortality in cancer
patients [34,35]. Social distancing is known to have negative health
consequences and increase risk for premature mortality during
normal times [36], but it also enhances patients’ feelings of un-
certainty associated with their prognosis. It is now well docu-
mented that perceived uncertainty increases individual emotional
distress and this in turn has negative effects on clinical outcomes in
cancer patients [37,38]. Three main aspects explain such uncer-
tainty: patients’ perception of the impact of social isolation and of
the healthcare crisis to access the cancer center to continue treat-
ments; the risk of being infected when accessing the cancer center;
and the need to change daily habits, especially those recommended
by health professionals as affecting well-being and clinical out-
comes, such as physical activity. The need to be isolated to contain
the epidemics is a stark contrast to what is normally recommended
for cancer patients including the importance of outdoor physical
exercise and of maximizing social supports.
To deal with the increased risk of distress and psychological
disorders and the obligation to adhere to social isolation, tele-
medicine has been used also by psychologists and psychiatrists to
guarantee psychological individual and group support for patients
while limiting visits to the cancer center. In order to propose the
adequate support to patients, psychological status and associated
contributing factors should bemonitored at different time points of
the care pathway. Hospital Anxiety and Depression Scale (HADS) is
an easy to use questionnaire and has a good accuracy in assessing
anxiety and depression in cancer patients [39]. Furthermore, even
in presence of low levels of depression and anxiety it will be crucial
to identify critical levels of intolerance of uncertainty and feelings
of loneliness in order to implement interventions to decrease the
risk of further distress and psychopathological complications.
Conclusions
In the context of the COVID-19 pandemic, we recommended
that routine breast screening be suspended, and that patients with
early and advanced breast cancer be treated as outpatients as much
as possible at the nearest medical center. Exams and appointments
of patients on follow-up or under adjuvant endocrine therapy
should either be postponed or managed through telemedicine.
Treatment should follow international guidelines, as much as
possible, but efforts should be made to minimize the number of
hospital visits. All treatment decisions should be taken in the
context of a multidisciplinary tumour board, which may take place
virtually. All treatment decision-making should balance risk and
benefits of treatment in the context of the specific pandemic level,
on a case by case discussion, always including patients’ preferences.
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